Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2023

Open Access 01-12-2023 | Empagliflozin | Correction

Correction: Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis

Authors: Michal Sitina, Marek Lukes, Vladimir Sramek

Published in: BMC Endocrine Disorders | Issue 1/2023

Login to get access

Excerpt

Correction: BMC Endocr Disord 23, 81 (2023).
Metadata
Title
Correction: Empagliflozin-associated postoperative mixed metabolic acidosis. Case report and review of pathogenesis
Authors
Michal Sitina
Marek Lukes
Vladimir Sramek
Publication date
01-12-2023
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2023
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-023-01436-w

Other articles of this Issue 1/2023

BMC Endocrine Disorders 1/2023 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine